A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors-Reference-Cited by-同舟云学术

A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors

Published:2017-04-17 Issue:1 Volume:36 Page:36-44
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Mehnert Janice M.,Edelman Gerald,Stein Mark,Camisa Heather,Lager Joanne,Dedieu Jean-François,Ghuysen Anne-Frédérique,Sharma Jyoti,Liu Li,LoRusso Patricia M.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/article/10.1007/s10637-017-0467-7/fulltext.html

Reference24 articles.

1. van der Heijden MS, Bernards R (2010) Inhibition of the PI3K pathway: hope we can believe in? Clin Cancer Res 16:3094–3099

2. Courtney KD, Corcoran RB, Engelman JA (2010) The PI3K pathway as drug target in human cancer. J Clin Oncol 28:1075–1083

3. Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296:1655–1657

4. Guillermet-Guibert J, Bjorklof K, Salpekar A, Gonella C, Ramadani F, Bilancio A, Meek S, Smith AJ, Okkenhaug K, Vanhaesebroeck B (2008) The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci U S A 105:8292–8297

5. Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7:606–619

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and therapeutic potential of DNA-dependent protein kinase inhibitors;Bioorganic Chemistry;2024-09

2. Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers;International Journal of Molecular Sciences;2024-02-06

3. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease;Signal Transduction and Targeted Therapy;2023-10-02

4. Exploratory Food Effect Assessment in Patients in Early Clinical Development of Oncology Drugs;Clinical Pharmacology & Therapeutics;2023-05-26

5. PI3K Inhibitor Eruptions: an Overview of Diagnostic and Management Strategies for the Inpatient Dermatologist;Current Dermatology Reports;2022-07-14